Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study
Ganeem K. Juneja(Thrombosis and Atherosclerosis Research Institute), Paul Y. Kim(McMaster University Medical Centre), Matthew Castelo(University of Toronto), Bettina E. Hansen(Aarhus University), Patricia C. Liaw(Thrombosis and Atherosclerosis Research Institute), Claudio M. Martin(Western University), Marat Slessarev(Western University), Douglas D. Fraser(Western University), Joel O. Abraham(Princeton University), James E. Chessum(Thrombosis and Atherosclerosis Research Institute), Peter L. Gross(Thrombosis and Atherosclerosis Research Institute), Jeffrey I. Weitz(McMaster University Medical Centre), Scott McGilvray(University of Toronto), Calvin H. Yeh(Athinoula A. Martinos Center for Biomedical Imaging), Samantha E. Cerroni(Thrombosis and Atherosclerosis Research Institute), Dhruva J. Dwivedi(Thrombosis and Atherosclerosis Research Institute), Erblin Cani(Thrombosis and Atherosclerosis Research Institute)
Cited by 64
Related Papers
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
|New England Journal of Medicine|1999|5.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
|New England Journal of Medicine|2017|1.1k
Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
|Journal of Clinical Investigation|1990|1.1k